EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

Efficacy of vancomycin lock therapy for totally implantable venous access port-related infection due to coagulase-negative staphylococci in 100 patients with cancer

Matthieu Lafaurie, Claire Montlahuc, Solen Kerneis, Victoire de Lastours iD, Sophie Abgrall, Véronique Manceron, Carine Couzigou, Amélie Chabrol, Axelle de Raigniac, Xavier Lescure, Pascale Longuet, Philippe Lesprit und 3 weitere

Journal of Antimicrobial Chemotherapy · 03.05.2023 · 78 (5) · 1253-1258

DOI: 10.1093/jac/dkad083 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 04.04.2023. Verfasst von Matthieu Lafaurie und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France. Hauptthemen laut MEDLINE: Catheterization, Central Venous, Catheter-Related Infections, Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Data on the efficacy of vancomycin catheter lock therapy (VLT) for conservative treatment of totally implantable venous access port-related infections (TIVAP-RI) due to CoNS are scarce. The aim of this study was to evaluate the effectiveness of VLT in the treatment of TIVAP-RI due to CoNS in cancer patients.

Methods

This prospective, observational, multicentre study included adults with cancer treated with VLT for a TIVAP-RI due to CoNS. The primary endpoint was the success of VLT, defined as no TIVAP removal nor TIVAP-RI recurrence within 3 months after initiation of VLT. The secondary endpoint was 3 month mortality. Risk factors for VLT failure were also analysed.

Results

One hundred patients were included [men 53%, median age 63 years (IQR 53–72)]. Median duration of VLT was 12 days (IQR 9–14). Systemic antibiotic therapy was administered in 87 patients. VLT was successful in 44 patients. TIVAP could be reused after VLT in 51 patients. Recurrence of infection after completion of VLT occurred in 33 patients, among which TIVAP was removed in 27. Intermittent VLT (antibiotic solution left in place in the TIVAP lumen part of the time) was identified as a risk factor for TIVAP-RI recurrence. At 3 months, 26 deaths were reported; 1 (4%) was related to TIVAP-RI.

Conclusions

At 3 months, success of VLT for TIVAP-RI due to CoNS was low. However, removing TIVAP was avoided in nearly half the patients. Continuous locks should be preferred to intermittent locks. Identifying factors of success is essential to select patients who may benefit from VLT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Catheterization, Central VenousCatheter-Related InfectionsNeoplasmsMaleAdultHumansMiddle AgedVancomycinCoagulaseProspective StudiesCatheters, IndwellingAnti-Bacterial AgentsStaphylococcus

Substanzen

VancomycinCoagulaseAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Infectious Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France.
  • Department of Biostatistics, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis and Université Paris Cité, INSERM S 717, Paris, France.
  • Equipe de Prévention du Risque Infectieux (EPRI), Assistance Publique-Hôpitaux de Paris, Hôpital Bichat and IAME Research Group, UMR 1137, Université Paris Cité and INSERM, Paris, France.
  • Department of Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hôpital Beaujon, Clichy, France and IAME Research Group, UMR 1137, Université Paris Cité and INSERM, Paris, France.
  • Department of Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hôpital Antoine Béclère Clamart, France and Université Paris-Saclay, INSERM U1018, Le Kremlin-Bicêtre, France.
  • Department of Internal Medicine, Centre Hospitalier de Nanterre, France.

ORCID-Profile: Victoire de Lastours

Zitieren

APA

Lafaurie, M., Montlahuc, C., Kerneis, S., de Lastours, V., Abgrall, S., Manceron, V., Couzigou, C., Chabrol, A., de Raigniac, A., Lescure, X., Longuet, P., Lesprit, P., Vanjak, D., Lepeule, R., & Groupe des référents en Infectiologie d’Ile de France (GRIF) (2023). Efficacy of vancomycin lock therapy for totally implantable venous access port-related infection due to coagulase-negative staphylococci in 100 patients with cancer. Journal of Antimicrobial Chemotherapy, 78(5), 1253-1258. https://doi.org/10.1093/jac/dkad083

Vancouver

Lafaurie M, Montlahuc C, Kerneis S, de Lastours V, Abgrall S, Manceron V, et al. Efficacy of vancomycin lock therapy for totally implantable venous access port-related infection due to coagulase-negative staphylococci in 100 patients with cancer. Journal of Antimicrobial Chemotherapy. 2023;78(5):1253-1258. doi:10.1093/jac/dkad083

BibTeX
@article{Lafaurie2023,
  author = {Lafaurie, Matthieu and Montlahuc, Claire and Kerneis, Solen and de Lastours, Victoire and Abgrall, Sophie and Manceron, Véronique and Couzigou, Carine and Chabrol, Amélie and de Raigniac, Axelle and Lescure, Xavier and Longuet, Pascale and Lesprit, Philippe and Vanjak, Dominique and Lepeule, Raphael and Groupe des référents en Infectiologie d’Ile de France (GRIF), Groupe des référents en Infectiologie d’Ile de France (GRIF)},
  title = {Efficacy of vancomycin lock therapy for totally implantable venous access port-related infection due to coagulase-negative staphylococci in 100 patients with cancer},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2023},
  volume = {78},
  number = {5},
  pages = {1253--1258},
  doi = {10.1093/jac/dkad083}
}
Kostenlos starten →